Pfizer’s colon cancer combo approval further supported by Phase III win
Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in…
All articles by Joshua Silverwood
Joshua Silverwood
-
-
ITM’s radiotherapeutic beats out standard-of-care in Phase III trial
ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)…
-
European supergroup launches to tackle diversity in clinical trials
A new pan-European initiative aimed at creating a new less fragmented and more democratic ecosystem for clinical trials across the…
-
XBiotech halts all rheumatology research after missing Phase II endpoints
XBiotech’s stock price has taken a hit after it announced a complete halt to its clinical program in rheumatological diseases…
-
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations…
-
CTO Europe 2024: keep the burden of trials away from patients, say experts
Major themes of taking the burden of oncological clinical trials away from the patients themselves to stabilise and streamline research…
-
New Amsterdam stock jumps as LDL-C lowering drug scores again at Phase III
New Amsterdam Pharma’s obicetrapib has exceeded company expectations in the Phase III BROADWAY trial in adult patients with atherosclerotic cardiovascular…
-
Daiichi Sankyo secures breakthrough designation for NSCLC treatment
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Daiichi Sankyo for its antibody-drug conjugate (ADC)…
-
CEO of UnitedHealthcare, Brian Thompson, shot dead in New York City
The CEO of US healthcare insurance firm UnitedHealthcare Group has been shot dead by a masked gunman outside of the…
-
Baxter signs over kidney care arm to investment firm in $3.5bn deal
US medtech giant Baxter has announced today (13 August) the signing of a definitive agreement divesting itself of the kidney…